Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772889 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 971
- Enrollment target
NCT00772889 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 971 participants.
The verdict
NCT00772889, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 971 participants
- Enrollment target
Study Summary
The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).
Interventions
- BIOLOGICAL Influenza vaccine GSK2186877A
- BIOLOGICAL GSK Biologicals' Fluarix™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 971 participants |
| Start Date | 2008-10-09 |
| Est. Completion | 2009-12-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00772889
The ClinicalTrials.gov registry entry for NCT00772889 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 971 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Influenza vaccine GSK2186877A is the first listed.
NCT00772889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00772889 about?
NCT00772889 is a clinical study titled "Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly". The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).
What is the current status of trial NCT00772889?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 971 participants. The study started on 2008-10-09. Estimated completion is 2009-12-15.
What interventions are being tested in trial NCT00772889?
The interventions under investigation include: Influenza vaccine GSK2186877A (BIOLOGICAL), GSK Biologicals' Fluarix™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT00772889?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.